Efficacy and tolerability of lasmiditan, an oral 5-HT1F receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study

Färkkilä, Markus; Diener, Hans‐Christoph; Géraud, G; Láinez, Miguel J. A.; Schoenen, Jean; Harner, Nadja; Pilgrim, Alison; Reuter, Uwe

doi:10.1016/s1474-4422(12)70047-9

Cited by 165 publications

(151 citation statements)

References 17 publications

Supporting

Mentioning

143

Contrasting

Unclassified

Order By: Relevance

“…Within that analysis, attacks with a baseline of moderate or severe pain (13), or of mild pain (14) are reported separately, given the data from the triptan development programs (15) and evidence that placebo rates for patients with moderate or severe pain at baseline are less (16). Pain free was used as the endpoint as development programs with this endpoint consistently report lower placebo rates than for the headache response outcome (for example, Ferrari et al (8), Ho et al (17), and Farkkila et al (18)), and it is the current International Headache Society guidance (19). Pain relief (13), moderate or severe pain at baseline reduced to nil or mild pain at two hours is also reported.…”

Section: Discussionmentioning

confidence: 99%

Effect of noninvasive vagus nerve stimulation on acute migraine: An open-label pilot study

et al. 2014

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of noninvasive vagus nerve stimulation on acute migraine: An open-label pilot study

et al. 2014

View full text Add to dashboard Cite

show abstract

“…The use of pure 5-HT 1F agonists is hypothesized could be effective as antimigraine abortive treatment due to higher receptor selectivity (26). However, recently clinical studies about 5-HT 1F receptor agonist, lasmiditan, revealed a high rate of central nervous system side effects in clinical trials included dizziness (often classified as severe), paresthesia, fatigue and vertigo (86,87). Novel antimigraine drugs without peripheral vasoconstrictor side effects are still needed; compounds binding specifically to 5-HT 1D , 5-HT 1F and 5-HT 7 receptors have been or are currently being investigated.…”

Section: -Ht Receptor Agonistmentioning

confidence: 99%

Migraine in the era of precision medicine

Zhang

Dong

Yu³

2016

Ann. Transl. Med.

View full text Add to dashboard Cite

Migraine is a common neurovascular disorder in the neurologic clinics whose mechanisms have been explored for several years. The aura has been considered to be attributed to cortical spreading depression (CSD) and dysfunction of the trigeminovascular system is the key factor that has been considered in the pathogenesis of migraine pain. Moreover, three genes (CACNA1A, ATP1A2, and SCN1A) have come from studies performed in individuals with familial hemiplegic migraine (FHM), a monogenic form of migraine with aura. Therapies targeting on the neuropeptids and genes may be helpful in the precision medicine of migraineurs. 5-hydroxytryptamine (5-HT) receptor agonists and calcitonin gene-related peptide (CGRP) receptor antagonists have demonstrated efficacy in the acute specific treatment of migraine attacks. Therefore, ongoing and future efforts to find new vulnerabilities of migraine, unravel the complexity of drug therapy, and perform biomarker-driven clinical trials are necessary to improve outcomes for patients with migraine.

show abstract

“…However, some patients have developed dose-dependent side effects such as paresthesia, dizziness, fatigue, and nausea. Notably, dizziness was experienced by 26 % of subjects receiving the 100 mg dose vs. 0 % of patients receiving placebo [6]. A phase 3 trial studying lasmiditan for acute migraine treatment is planned.…”

Section: Serotonin Receptor Agonistsmentioning

confidence: 99%

Emerging treatments for the primary headache disorders

2015

View full text Add to dashboard Cite

Migraine and cluster headache are common, episodic, often chronic and disabling disorders of the brain. Although there are many standard treatment techniques, none are ideal. This article reviews various novel pharmacologic and device-related treatments for migraine and cluster headache. Emphasis is given to recent advances in the development of monoclonal antibodies (mAbs) targeting calcitonin gene-related peptide (CGRP) and its receptor, including promising results from phase 2 trials studying the safety and efficacy of LY2951742, ALD403 and TEV-48125, three anti-CGRP mAbs. Other new pharmacologic treatments discussed include the 5-HT1F receptor agonist lasmiditan and glial cell modulator ibudilast. Also reviewed is neuromodulation for migraine and cluster headache, including promising recent results of randomized controlled trials studying sphenopalatine ganglion stimulation, trigeminal nerve stimulation, transcutaneous vagus nerve stimulation, and transcranial magnetic stimulation. Finally, we discuss patch, inhaled, and intranasal methods of triptan and dihydroergotamine delivery.

show abstract

Efficacy and tolerability of lasmiditan, an oral 5-HT1F receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study

Cited by 165 publications

References 17 publications

Effect of noninvasive vagus nerve stimulation on acute migraine: An open-label pilot study

Effect of noninvasive vagus nerve stimulation on acute migraine: An open-label pilot study

Migraine in the era of precision medicine

Emerging treatments for the primary headache disorders

Contact Info

Product

Resources

About